Early targeted antimicrobial therapy and source control during sepsis
Cube Dx was founded in 2015 and is located in St. Valentin (Austria). The company focuses on the development, production and distribution of multiplex tests for in-vitro diagnostics in clinical routine. Multiplex diagnostics allow for parallel identification of a variety of significant parameters (bacteria, fungi, resistance markers etc.) in a single test, requiring only a minimal amount of sample material.
SEPSIS – A KILLER
Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection (Sepsis-3 definition). In 2017, the World Health Organisation (WHO) declared sepsis to be a world health priority.
PATHOGEN IDENTIFICATION IN JUST 3 HOURS – FROM WHOLE BLOOD
Cube Dx technology identifies pathogens directly from whole blood in just 3 hours, enabling early, targeted therapy.
BROAD SPECTRUM OF PATHOGENS TESTED
100 microbial species (bacteria, fungi) and resistance genes from just one test to detect clinically relevant pathogens.
